All In MedTech

Device Trial Radar · NCT07830797

Absorbable Hemostatic Fluid Gelatin Trial

A Multicenter, Single-Blind, Randomized Controlled Clinical Trial of the Safety and Efficacy of Absorbable Hemostatic Fluid Gelatin for Surgical Hemostasis

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Sep 8, 2026

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Medprin Regenerative Medical Technologies Co., Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Southern Medical University, China; Xi'an Honghui Hospital; The Third Affiliated Hospital of Southern Medical University; Obstetrics & Gynecology Hospital of Fudan University; Zhejiang Provincial People's Hospital
First posted
Sep 21, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-blind, randomized controlled, non-inferiority trial evaluating the safety and efficacy of an absorbable hemostatic fluid gelatin for surgical hemostasis. Subjects are patients undergoing elective/semi-elective surgeries in General Surgery, Orthopedics, and Gynecology. The test group receives the investigational device, while the control group receives a marketed predicate device (SURGIFLO). The primary outcome is the 5-minute hemostasis success rate at the Target Bleeding Site (TBS).

Conditions

  • Surgical Bleeding

Interventions

  • Absorbable Hemostatic Fluid GelatinDevice

    Composed of fluid gelatin preloaded in a syringe with catheter components; gelatin derived from porcine skin. Applied to TBS and covered with moist gauze during surgery.

  • Absorbable Hemostatic Fluid Gelatin SURGIFLO Haemostatic MatrixDevice

    This product is a flowable hemostatic material made from a porcine skin-derived gelatin matrix, intended to control bleeding from capillaries, veins, and small arteries during surgical procedures

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-Minute Hemostasis Success RateTime frame: Intraoperative (Day of surgery)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.